Press Releases

06.27.2019

Pfizer Declares Third-Quarter 2019 Dividend

06.21.2019

European Commission Approves TALZENNA® (talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer

06.18.2019

Pfizer Invites Public to View and Listen to Webcast of July 30 Conference Call with Analysts

06.17.2019

Pfizer to Acquire Array BioPharma

06.12.2019

Pfizer Announces Results from XELJANZ® XR (tofacitinib) ORAL Shift Study, The First Phase 3b/4 Study to Evaluate Methotrexate Withdrawal with a JAK Inhibitor

06.05.2019

Jeff Settleman, Ph.D., Joins Pfizer to Lead Oncology Research & Development

05.24.2019

Pfizer Announces Top-Line Results from Phase 3 Trial of LYRICA® (pregabalin) in Primary Generalized Tonic-Clonic Seizures

05.15.2019

Pfizer Oncology to Showcase New Data from Innovative Science That Address Patient Needs at ASCO 2019 Annual Meeting

05.15.2019

Pfizer Announces Positive Top-Line Results from Phase 3 Study of Investigational Oral JAK1 Candidate, Abrocitinib (PF-04965842), in Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis

05.14.2019

FDA Approves BAVENCIO® (avelumab) Plus INLYTA® (axitinib) Combination for Patients with Advanced Renal Cell Carcinoma

05.09.2019

Pfizer Opens New State-Of-The-Art Biologics Clinical Manufacturing Facility In Andover, Massachusetts

05.08.2019

Pfizer Acquires Clinical-Stage Biotech Therachon